No insider purchase over the last 90 days. The latest was filed 14 Jul 2026.
Adherium Limited is a listed company. Filings by its managers are published through ASX. Between 18 October 2025 and 18 October 2026, 4 insiders published 6 filings.
The flow runs one way only: 1 insider bought (3 purchases) and nobody sold on the market. The totals do not cover 3 filings with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. On the buying side, the filings list 1 senior executive among the declarants.
The last insider purchase was made public on 14 July 2026, 96 days ago.
With 6 filings in twelve months, the company is more active than the median of 3 filings across the 2,222 companies we follow on the same exchange. Since 2026, the database holds 3 purchases and no sales by insiders of the company.
These figures are compiled from regulatory filings published by ASX. They describe what insiders did and are not a recommendation.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
FY ended June 2024 · cache
6 of 6 declarations
Adherium Limited is a company listed on the Australian Securities Exchange, focused on developing health management solutions. It aims to improve treatment adherence for patients with respiratory diseases.